Development and evaluation of adsorption sheet (HD safe sheet-U) using active carbon for the purpose of the preventing the contamination diffusion of urinary excreted anticancer drug

Table 4 Adhesion to the slipper sole of urinary anticancer drug dropped on the sheet

Anticancer drug	Dropping amount (μg)	No sheet	Control sheet 1	Control sheet 2	HD safe Sheet-U
CPA	2000	367.8 ± 16.3	355.3 ± 59.0	256.3 ± 44.3^**	ND
IFM	1000	142.4 ± 26.8	32.5 ± 3.3	21.2 ± 2.2^***	16.8 ± 2.1^{*** †}
CBDCA	5000	275.2 ± 56.7	16.1 ± 5.0	11.9 ± 3.7	1.5 ± 0.5^{*** ††}
CDDP	100	0.7 ± 0.2	0.3 ± 0.1	0.3 ± 0.1	0.2 ± 0.1^*
MTX	6000	1183.1 ± 130.6	78.0 ± 6.4	53.6 ± 7.8^***	5.0 ± 1.6^{*** †††}
5-FU	1000	88.1 ± 9.1	5.1 ± 1.3	4.0 ± 0.3	3.8 ± 0.1
Ara-C	1000	137.4 ± 51.5	45.3 ± 15.8	3.1 ± 1.1^***	LOQ
GEM	300	45.8 ± 8.5	27.4 ± 5.4	1.5 ± 0.1	LOQ
ADR	1000	198.7 ± 30.9	25.9 ± 3.7	7.7 ± 1.6^***	LOQ
Epi-ADR	1000	8.8 ± 0.8	0.7 ± 0.2	0.9 ± 0.2^***	0.6 ± 0.2
PTX	200	27.6 ± 9.5	LOQ	LOQ	LOQ
DTX	200	34.2 ± 7.1	2.7 ± 1.8	0.5 ± 0.0^*	ND
VP-16	500	118.2 ± 29.5	3.4 ± 1.4	1.5 ± 0.7^*	0.6 ± 0.1^*
CPT-11	1500	63.9 ± 34.5	LOQ	LOQ	LOQ

The numerical value indicated mean ± standard deviation (μg)(n = 4), **P < 0.01, ***P < 0.001 vs. Control sheet 1, ^†† P < 0.01, ^††† P < 0.001 vs. Control sheet 2 by Fisher’s least significant difference test. LOQ limit of quantitation (Ara-C; <0.5μg, GEM; <0.5μg, ADR;<5.0μg, PTX; <2.5μg, CPT-11; <2.5μg). ND No peak detection

ISSN: 2055-0294